Context Therapeutics Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. The company is a pre-revenue biopharmaceutical developer focused on solid tumors. Its principal program is preclinical candidate CTIM-76, an anti-CD3 x anti-CLDN6 bispecific antibody. In March 2023, Context discontinued ONA-XR development and shifted resources to CTIM-76.
Financial results and position
- Revenue: None reported; the company has not generated product revenue. Profit margins are not meaningful.
- Q2 2023: Net loss was $5.0 million, or $0.31 per share, versus $4.0 million, or $0.25 per share, in Q2 2022. Operating expenses were $5.3 million, up 32% year over year.
- First six months: Net loss was $11.3 million, or $0.71 per share, versus $7.4 million, or $0.47 per share, in the first half of 2022. R&D expense rose 179% to $8.0 million; G&A declined 3% to $4.0 million.
- R&D drivers: First-half CTIM-76 expense was $5.4 million, up $5.3 million year over year, mainly from manufacturing and preclinical work. Q2 ONA-XR R&D included a $167,312 credit, as actual and estimated closeout costs were below the amount accrued at March 31.
- Cash flow: Operating cash use was $10.4 million in the first half, compared with $6.6 million in 2022. There were no investing or financing cash flows in the 2023 period.
- Liquidity and debt: Cash and cash equivalents were $25.1 million at June 30, down from $35.5 million at December 31, 2022. Total liabilities were $3.8 million, primarily accounts payable and accrued expenses; no debt or credit facility was reported. Accumulated deficit was $55.4 million.
- Other metrics: Interest income was $0.6 million for the first half, versus $27,000 a year earlier, reflecting higher interest earned on cash balances. Cash equivalents included $23.6 million in money market accounts.
Changes, outlook, and risks
- Management said existing cash was expected to fund operations into late 2024; the liquidity note separately states cash was sufficient for at least 12 months from the financial statements’ issuance date. These estimates depend on assumptions and may prove inaccurate.
- Management expected to submit a CTIM-76 IND application to the FDA in Q1 2024 and provide additional preclinical data by year-end 2023. These are plans, not assured outcomes.
- The company expects ongoing losses and significant R&D spending, and says substantial additional financing will be needed. Future capital may come from equity, debt, partnerships, collaborations, or other arrangements; availability and terms are not assured. Financing could dilute shareholders or require concessions of rights.
- Integral Molecular may receive approximately $55 million in remaining development and regulatory milestones, up to $130 million in sales milestones, and tiered royalties up to 12% under the licensing agreement. The agreement was amended in March 2023 to remove a milestone and revise a later milestone, including potential payment for third-party research funding used by Integral.
- Management does not anticipate further payments under the Tyligand ONA-XR process-development agreement following the program’s discontinuation. Tyligand’s separate license provides for potential royalties if sales occur in its territory.
- Key risks include clinical and regulatory failure, reliance on third-party researchers and manufacturers, need for additional capital, and uncertainty in product development and commercialization. The filing reported no material changes to previously disclosed risk factors and no material legal proceedings.
Key facts for investors to verify
- Whether CTIM-76 IND-enabling work and the planned Q1 2024 FDA submission proceed on schedule, and what the additional preclinical data show.
- Whether the late-2024 cash runway remains realistic as CTIM-76 manufacturing and development spending continues.
- Any subsequent financing, collaboration, or licensing transactions, including their dilution and economic terms.
- How the March 2023 Integral agreement amendment affects potential milestone obligations, and whether any ONA-XR closeout or Tyligand costs arise beyond management’s expectations.